Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer.
Ontology highlight
ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) remains recalcitrant to all forms of cancer treatment and carries a five-year survival rate of only 8%1. Inhibition of oncogenic KRAS (hereafter KRAS*), the earliest lesion in disease development that is present in more than 90% of PDACs, and its signalling surrogates has yielded encouraging preclinical results with experimental agents2-4. However, KRAS*-independent disease recurrence following genetic extinction of Kras* in mouse models anticipates the need for co-extinction strategies5,6. Multiple oncogenic processes are initiated at the cell surface, where KRAS* physically and functionally interacts to direct signalling that is essential for malignant transformation and tumour maintenance. Insights into the complex
SUBMITTER: Yao W
PROVIDER: S-EPMC6661074 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA